Morse RT, et al. - In 163 patients from 2011 to 2016, triweekly 100 mg/m2 with alternative weekly 40 mg/m2 vs weekly <40 mg/m2 cisplatin regimens were assessed in head and neck squamous cell carcinoma (HNSCC). Previously, they considered triweekly high-dose cisplatin (100 mg/m2) with concurrent radiation therapy as the standard of care in the comprehensive postoperative setting in HNSCC. They observed inferior outcomes with weekly cisplatin doses under 40 mg/m2, which suggested the inferiority of low-dose weekly chemotherapy.